Amicus, Biogen to collaborate on Parkinson's

|About: Amicus Therapeutics, Inc. (FOLD)|By:, SA News Editor

Amicus Therapeutics (FOLD) inks a collaboration deal with Biogen (BIIB) for the discovery, development, and commercialization of novel small molecules for the treatment of Parkinson's disease.

This is a preclinical venture. The two companies will seek to discover a new class of small molecules that target the GCase enzyme.

There are no upfront payments to FOLD.

BIIB will fund all discovery, development, and commercialization and will reimburse FOLD for the cost of employees working on the project.

FOLD is eligible for development and regulatory milestones and "modest" royalties. (PR)